Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

In a development that could reshape the bleak landscape of pancreatic cancer treatment, researchers have reported that a novel oral drug, daraxonrasib, halted tumour growth in the overwhelming majority of participants and rendered the disease undetectable in one in twelve patients.

Nov 21, 2026 - 17:03
0 4
Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

In a development that could reshape the bleak landscape of pancreatic cancer treatment, researchers have reported that a novel oral drug, daraxonrasib, halted tumour growth in the overwhelming majority of participants and rendered the disease undetectable in one in twelve patients. The findings, presented at a major oncology symposium in Barcelona, have been hailed as the most significant breakthrough for the disease in decades, offering a glimmer of hope for a cancer that remains the deadliest of the common malignancies in the UK and beyond.

The trial’s headline‑grabbing results

The phase II trial enrolled 61 patients who had recently been diagnosed with advanced pancreatic cancer that had already metastasised. Over an average follow‑up of 18 months, tumours stopped growing in 90 per cent of the cohort, and more than 60 per cent experienced tumour shrinkage or complete disappearance. Crucially, about eight per cent of participants saw their tumours become undetectable on CT scans, a result described by the trial’s lead investigator as “the closest to cure”.

Survival data reinforced the optimism. One year after commencing treatment, 76.6 per cent of patients were still alive – a stark contrast to the 40‑45 per cent survival rate typically seen with chemotherapy alone. While the drug is not yet a cure, the extension of life and the depth of tumour response mark a substantial shift from historical outcomes.

Understanding daraxonrasib’s mechanism

Daraxonrasib belongs to a new class of KRAS inhibitors. KRAS mutations drive the uncontrolled growth of pancreatic tumours, and the drug works by “locking on to and shutting off” these mutations, effectively throttling the tumour’s engine. Because KRAS alterations are present in the majority of pancreatic cancers, the therapy targets a fundamental driver of the disease rather than peripheral pathways.

The broader significance lies in the drug’s potential applicability to other malignancies that share KRAS mutations. Researchers suggest that the same molecular lock could, in theory, be employed against dozens of other cancers, although further trials are required to confirm efficacy beyond the pancreas.

Clinical context: why this matters

Pancreatic cancer has long been a statistical outlier. Half of all patients in the UK die within three months of diagnosis, and only about three per cent survive five years once the disease has spread. The survival gap between pancreatic cancer and other common cancers is stark, making any advance in treatment particularly noteworthy.

Current standard care relies heavily on chemotherapy, which offers modest benefits and considerable toxicity. The prospect of an oral pill that can arrest tumour growth and, in a minority of cases, render the disease invisible on imaging, could dramatically alter the therapeutic algorithm, shifting the focus from palliation to disease control.

Expert commentary on the breakthrough

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, underscored the unprecedented nature of the responses. “I have never seen so many tumours disappear in patients whose cancer had spread,” he told the Barcelona symposium. He highlighted not only the higher response rates but also the “near doubling in the duration of disease control”, suggesting that the survival advantage could widen as longer‑term data emerge.

Michelle Mitchell, chief executive of Cancer Research UK, tempered enthusiasm with a call for further research. While she praised the trial as “the biggest leap forward we’ve seen in decades”, she reminded that the treatment must still undergo extensive testing before it can be considered for NHS adoption. “More trials are now needed,” she said, acknowledging the still‑low overall survival for pancreatic cancer.

Limitations and unanswered questions

Despite the promising figures, the trial leaves several critical questions unanswered. The median follow‑up of 18 months, while longer than many early‑phase studies, does not reveal whether the disease can be kept at bay indefinitely. Some patients did not experience tumour disappearance, and the durability of response beyond the study period remains unknown.

Moreover, the safety profile of daraxonrasib was not detailed in the source material, leaving clinicians without a clear picture of potential adverse effects. As with any targeted therapy, resistance mechanisms may emerge, potentially limiting long‑term efficacy. These gaps underscore the necessity of larger, randomised phase III trials that compare the pill directly against standard chemotherapy regimens.

Implications for NHS policy and future research

Should subsequent trials confirm the early benefits, the NHS will face decisions about funding and integrating a novel oral agent into its oncology pathways. The drug’s oral administration could simplify logistics compared with infusion‑based chemotherapy, potentially reducing hospital visits and associated costs. However, pricing, reimbursement, and equitable access will be central considerations for policymakers.

Beyond pancreatic cancer, the KRAS‑targeting strategy may spark a wave of parallel investigations into other KRAS‑driven tumours, such as certain lung and colorectal cancers. The trial’s success could accelerate investment in molecularly guided therapies, reinforcing the shift towards precision oncology within the UK’s research agenda.

What patients and families can expect next

For patients currently battling advanced pancreatic cancer, the news offers a measured dose of hope. While daraxonrasib is not yet available outside clinical trials, the promising survival figures and deep tumour responses suggest that enrolment in forthcoming studies may become a priority for many. Advocacy groups are likely to push for rapid expansion of trial sites, including within the UK, to give more patients access to the experimental therapy.

In the meantime, clinicians will continue to rely on existing chemotherapy protocols, but the prospect of an oral drug that can dramatically slow or even erase tumour growth reshapes the conversation around prognosis. As the data mature, the oncology community will watch closely to see whether daraxonrasib can truly deliver on its early promise and rewrite the narrative of a disease that has long seemed almost inevitably fatal.

This article was produced with AI-assisted research and editorial support. Reporting is based on the source material cited below. Sources: The Guardian UK; theguardian.com; Global1.News (21 November 2026).

By Erica Thornton, Staff Writer

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Wow Wow 0
Sad Sad 0
Angry Angry 0
Erica Thornton

US Politics and Policy Correspondent at Global1.News. Based in Washington DC, covering American politics, policy, elections, and the courts. Knows how the system works and tells you what it actually means.

Comments (0)

User